Heather Wakelee, MD, Stanford University
Articles by Heather Wakelee, MD, Stanford University
Second-Line Treatment of SCLC
ByJohn V. Heymach, MD, PhD, MD Anderson Cancer Center,Heather Wakelee, MD, Stanford University,Ani Balmanoukian, MD, The Angeles Clinic and Research Institute,Stephen Liu, MD, Georgetown University,Sandip P. Patel, MD, UC San Diego Health,Vamsidhar Velcheti, MD, NYU Langone Health Vamsidhar Velcheti, MD, leads the discussion on the current standard of care and approaching the treatment of second-line SCLC.
Updated Results of the CASPIAN Trial in SCLC From ESMO 2021
ByJohn V. Heymach, MD, PhD, MD Anderson Cancer Center,Heather Wakelee, MD, Stanford University,Ani Balmanoukian, MD, The Angeles Clinic and Research Institute,Stephen Liu, MD, Georgetown University,Sandip P. Patel, MD, UC San Diego Health,Vamsidhar Velcheti, MD, NYU Langone Health John V. Heymach, MD, PhD, reviews updated results from the phase III CASPIAN trial for patients with extensive-stage SCLC (small cell lung cancer) as presented at ESMO 2021.
Immunotherapies in the Treatment of Extensive-Stage SCLC
ByJohn V. Heymach, MD, PhD, MD Anderson Cancer Center,Heather Wakelee, MD, Stanford University,Ani Balmanoukian, MD, The Angeles Clinic and Research Institute,Stephen Liu, MD, Georgetown University,Sandip P. Patel, MD, UC San Diego Health,Vamsidhar Velcheti, MD, NYU Langone Health Sandip P. Patel, MD, reviews results and clinical implications from the CASPIAN study, and Heather Wakelee, MD, shares insight on approaching the optimal immunotherapy option for patients with extensive-stage SCLC.
IMpower133 Trial for Extensive-Stage SCLC
ByJohn V. Heymach, MD, PhD, MD Anderson Cancer Center,Heather Wakelee, MD, Stanford University,Ani Balmanoukian, MD, The Angeles Clinic and Research Institute,Stephen Liu, MD, Georgetown University,Sandip P. Patel, MD, UC San Diego Health,Vamsidhar Velcheti, MD, NYU Langone Health Stephen Liu, MD, reviews outcomes from the IMpower133 trial and comments on the current standard of care for the first-line treatment of extensive-stage SCLC.
Treatment Options for Limited-Stage SCLC
ByJohn V. Heymach, MD, PhD, MD Anderson Cancer Center,Heather Wakelee, MD, Stanford University,Ani Balmanoukian, MD, The Angeles Clinic and Research Institute,Stephen Liu, MD, Georgetown University,Sandip P. Patel, MD, UC San Diego Health,Vamsidhar Velcheti, MD, NYU Langone Health John V. Heymach, MD, PhD, provides an overview of small cell lung cancer (SCLC), and Ani Balmanoukian, MD, reviews available treatment options for limited-stage disease.
Treatment of Advanced NSCLC Following Progression on Immunotherapy
ByJohn V. Heymach, MD, PhD, MD Anderson Cancer Center,Heather Wakelee, MD, Stanford University,Ani Balmanoukian, MD, The Angeles Clinic and Research Institute,Stephen Liu, MD, Georgetown University,Sandip P. Patel, MD, UC San Diego Health,Vamsidhar Velcheti, MD, NYU Langone Health Lung cancer experts provide insight on updates from key clinical trials presented at ESMO 2021 on PD-1 inhibitor–resistant NSCLC.
Role of Immunotherapy in Early Stage NSCLC Treatment
ByJohn V. Heymach, MD, PhD, MD Anderson Cancer Center,Heather Wakelee, MD, Stanford University,Ani Balmanoukian, MD, The Angeles Clinic and Research Institute,Stephen Liu, MD, Georgetown University,Sandip P. Patel, MD, UC San Diego Health,Vamsidhar Velcheti, MD, NYU Langone Health Dr Heather Wakelee reviews results from the IMpower110 study for first-line metastatic NSCLC treatment.
Updates From CheckMate 9LA and POSEIDON Studies in Advanced NSCLC
ByJohn V. Heymach, MD, PhD, MD Anderson Cancer Center,Heather Wakelee, MD, Stanford University,Ani Balmanoukian, MD, The Angeles Clinic and Research Institute,Stephen Liu, MD, Georgetown University,Sandip P. Patel, MD, UC San Diego Health,Vamsidhar Velcheti, MD, NYU Langone Health Heather Wakelee, MD, shares updates from the CheckMate 9LA study, and Vamsidhar Velcheti, MD, reviews key data from the phase 3 POSEIDON study for patients with NSCLC.
Chemoimmunotherapy in Advanced NSCLC Treatment
ByJohn V. Heymach, MD, PhD, MD Anderson Cancer Center,Heather Wakelee, MD, Stanford University,Ani Balmanoukian, MD, The Angeles Clinic and Research Institute,Stephen Liu, MD, Georgetown University,Sandip P. Patel, MD, UC San Diego Health,Vamsidhar Velcheti, MD, NYU Langone Health Experts in lung cancer discuss recent updates from ESMO 2021 and IASLC 2021 WCLC on combination immunotherapy plus chemotherapy for the treatment of advanced NSCLC.
Treatment of Advanced NSCLC With Dual Immune Checkpoint Inhibitors: 4-Year Update of CheckMate 227
ByJohn V. Heymach, MD, PhD, MD Anderson Cancer Center,Heather Wakelee, MD, Stanford University,Ani Balmanoukian, MD, The Angeles Clinic and Research Institute,Stephen Liu, MD, Georgetown University,Sandip P. Patel, MD, UC San Diego Health,Vamsidhar Velcheti, MD, NYU Langone Health Sandip P. Patel, MD, reviews updates on dual immunotherapy agents for the treatment of advanced NSCLC including the 4-year update from the CheckMate 227 study.
Treatment of Advanced NSCLC With Immune Checkpoint Inhibitors
ByJohn V. Heymach, MD, PhD, MD Anderson Cancer Center,Heather Wakelee, MD, Stanford University,Ani Balmanoukian, MD, The Angeles Clinic and Research Institute,Stephen Liu, MD, Georgetown University,Sandip P. Patel, MD, UC San Diego Health,Vamsidhar Velcheti, MD, NYU Langone Health Drs Vamsidhar Velcheti, Ani Balmanoukian, Heather Wakelee, and Stephen Liu discuss recent updates on single-agent immunotherapy regimens in patients with NSCLC.
Treating ALK-Mutant and KRAS G12C–Mutant NSCLC
ByJohn V. Heymach, MD, PhD, MD Anderson Cancer Center,Heather Wakelee, MD, Stanford University,Ani Balmanoukian, MD, The Angeles Clinic and Research Institute,Stephen Liu, MD, Georgetown University,Sandip P. Patel, MD, UC San Diego Health,Vamsidhar Velcheti, MD, NYU Langone Health Lung cancer experts share updates in the treatment of ALK-mutant NSCLC and KRAS G12C–mutant NSCLC as seen in the CROWN study, BrigALK2 real-world study, and CODEBreaK 100 study.
Treatment of MET Exon 14 Mutations in NSCLC
ByJohn V. Heymach, MD, PhD, MD Anderson Cancer Center,Heather Wakelee, MD, Stanford University,Ani Balmanoukian, MD, The Angeles Clinic and Research Institute,Stephen Liu, MD, Georgetown University,Sandip P. Patel, MD, UC San Diego Health,Vamsidhar Velcheti, MD, NYU Langone Health Heather Wakelee, MD, reviews key data for the treatment of MET exon 14 mutations in NSCLC as seen in the GeoMETry-III trial and the CRYSALIS study.
Treating EGFR Exon 20 Insertions and HER2-Mutant NSCLC
ByJohn V. Heymach, MD, PhD, MD Anderson Cancer Center,Heather Wakelee, MD, Stanford University,Ani Balmanoukian, MD, The Angeles Clinic and Research Institute,Stephen Liu, MD, Georgetown University,Sandip P. Patel, MD, UC San Diego Health,Vamsidhar Velcheti, MD, NYU Langone Health Dr Vamsidhar Velcheti evaluates the use of mobocertinib in patients with EGFR exon 20 insertions, and Drs John V. Heymach and Sandip P. Patel discuss the treatment of HER2-mutant NSCLC.
Treatment of TKI-Refractory EGFR-Mutant NSCLC
ByJohn V. Heymach, MD, PhD, MD Anderson Cancer Center,Heather Wakelee, MD, Stanford University,Ani Balmanoukian, MD, The Angeles Clinic and Research Institute,Stephen Liu, MD, Georgetown University,Sandip P. Patel, MD, UC San Diego Health,Vamsidhar Velcheti, MD, NYU Langone Health Heather Wakelee, MD, and Stephen Liu, MD, review the treatment of TKI-refractory EGFR-mutant NSCLC.
Recent Updates in EGFR-Mutant NSCLC Treatment Landscape
ByJohn V. Heymach, MD, PhD, MD Anderson Cancer Center,Heather Wakelee, MD, Stanford University,Ani Balmanoukian, MD, The Angeles Clinic and Research Institute,Stephen Liu, MD, Georgetown University,Sandip P. Patel, MD, UC San Diego Health,Vamsidhar Velcheti, MD, NYU Langone Health Experts in lung cancer provide insight on recent updates from the ESMO Congress 2021 for the treatment of EGFR-mutant NSCLC.
Sequencing Treatments in EGFR-Mutant NSCLC
ByJohn V. Heymach, MD, PhD, MD Anderson Cancer Center,Heather Wakelee, MD, Stanford University,Ani Balmanoukian, MD, The Angeles Clinic and Research Institute,Stephen Liu, MD, Georgetown University,Sandip P. Patel, MD, UC San Diego Health,Vamsidhar Velcheti, MD, NYU Langone Health Vamsidhar Velcheti, MD, and Stephen Liu, MD, discuss their treatment approaches for patients with EGFR-mutant NSCLC who progress on osimertinib.
Selecting First-line Treatment for EGFR-Mutant NSCLC
ByJohn V. Heymach, MD, PhD, MD Anderson Cancer Center,Heather Wakelee, MD, Stanford University,Ani Balmanoukian, MD, The Angeles Clinic and Research Institute,Stephen Liu, MD, Georgetown University,Sandip P. Patel, MD, UC San Diego Health,Vamsidhar Velcheti, MD, NYU Langone Health Heather Wakelee, MD, shares insight on factors to consider when approaching the optimal first-line therapy for patients with EGFR-mutant advanced NSCLC.
Treatment Landscape for EGFR-Mutant Advanced NSCLC
ByJohn V. Heymach, MD, PhD, MD Anderson Cancer Center,Heather Wakelee, MD, Stanford University,Ani Balmanoukian, MD, The Angeles Clinic and Research Institute,Stephen Liu, MD, Georgetown University,Sandip P. Patel, MD, UC San Diego Health,Vamsidhar Velcheti, MD, NYU Langone Health Ani Balmanoukian, MD, Sandip P. Patel, MD, and Heather Wakelee, MD, review currently available treatment options for EGFR-mutant advanced NSCLC and discuss their approach to frontline therapy.
Chemoimmunotherapy in Advanced NSCLC Treatment
Treatment of TKI-Refractory EGFR-Mutant NSCLC
Treating EGFR Exon 20 Insertions and HER2-Mutant NSCLC
Recent Updates in EGFR-Mutant NSCLC Treatment Landscape